The potential market is just ginormous. Even if just 1% of the world's diabetic population (400m+) were placed on apabetalone for some reason (diabetic/Cardio/Renal/Covid-Ace2 prophylaxis) as adjuntive therapy, and at a lower than likely annual ASP of $1000 (averaging down for China) ... still equals mega-blockbuster potential.

This 2014 study (sorry if outdated) estimates 43.5% of Type-2 Diabetes has CKD also. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091951/

More than 100 million Americans have Diabetes with approximately 90-95% Type 2 Diabetes, times 43.5% with CKD === over 30m people in America alone with Type 2 + CKD. All approximates, just looking for hand grenade range for the market potential. Even just 20% of this targeted sub-group on apabetalone == megablockbuster.

https://www.cdc.gov/media/releases/2017/p0718-diabetes-report.html

We need a partner asap, to get this moving forward asap. And hopefully get somewhere even close to some of those BoM numbers. Given the safety and previous BoM data, BTD, and potential market, seems like a very strong opportunity for somebody.

If we are able to indeed achieve a partnership and an "active" path toward progress (and NDA), I think RVX/apabetalone will become much more visible with that partnering news and new credibility, and with a cursory study of the potential market for the "first" molecule up to bat.

jmho and glta